 |
PLOS ONE. 18 (2): e0280942. ↑ Mensah, Fane; Bansal, Amolak; Berkovitz, Saul; Sharma, Arti; Reddy, Venkat; Leandro, Maria; Cambridge, Geraldine (2016). "Prolonged B cell phenotype in patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A cross-sectional examine". Clinical and Experimental Immunology. 184 (2): 237-247. doi:10.1111/cei.12749. ↑ Loebel, M; Grabowski, P; Heidecke, H; Bauer, S; Hanitsch, LG; Wittke, Okay; Meisel, C; Reinke, P; Volk, H; Fluge, ﾘ; Mella, O; Scheibenbogen, C (2016). "Antibodies to β adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome". Mind, habits, and immunity. ↑ Bradley, A S; Ford, B; Bansal, A S (March 11, 2013). "Altered practical B cell subset populations in patients with chronic fatigue syndrome in comparison with wholesome controls". Clinical and Experimental Immunology. 172 (1): 73-80. doi:10.1111/cei.12043. ↑ Fluge, ﾘystein; Mella, Olav (July 1, 2009). "Clinical impression of B-cell depletion with the anti-CD20 antibody rituximab in chronic fatigue syndrome: a preliminary case collection". ↑ "Assertion on Rituximab Trial and Analysis". Put money into ME Analysis.
Also visit my web-site - rituximab infusion side effects (https://www.facebook.com/rituximabprecio/) |